Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma
Trial Purpose and Description
The purpose of this study is to determine if Mammosite Catheter optimization using multiple dwell position delivery decreases skin toxicity over historically reported skin toxicity with the single dwell delivery method.
- 30 Years and older
- Life expectancy of at least two years.
- Stage 0, I, or II breast cancer. If stage II, the tumor size must be 3 cm or less.
- On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the
- Surgical treatment of the breast must have been lumpectomy. The margins of the
resected specimen must be histologically free of tumor (>2mm, DCIS and invasive).
Re-excision of surgical margins is permitted.
- Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 3 cm
or less. (Patients with microscopic multifocality are eligible as long as total
pathologic tumor size is 3 cm or less.)
- Patients with invasive breast cancer are required to have axillary staging which can
include sentinel node biopsy alone (if negative), sentinel node biopsy followed by
axillary dissection or sampling with a minimum total of 6 axillary nodes (if sentinel
node is positive), or axillary dissection alone (with a minimum of 6 axillary nodes).
(Axillary staging is NOT required for patients with DCIS.)
- The patient must have the MammoSite catheter placed within 4 weeks or 28 days of the
final surgery for their breast cancer (lumpectomy, re-excision of margins, or
axillary staging procedure). Placement of a spacer for the MammoSite catheter is
permitted at their final surgery.
- Patients with a history of non-ipsilateral breast malignancies are eligible if they
have been disease-free for 2 or more years prior to randomization. Patients with the
following cancers are eligible even if diagnosed and treated within the past 2 years:
carcinoma in situ of the cervix, colon, melanoma in situ, and basal cell and squamous
cell carcinoma of the skin. Patients with a prior diagnosis of ipsilateral breast
cancer are ineligible.
- Must have 3 or fewer histologically positive axillary nodes with no extracapsular
- Chemotherapy is permitted if planned for =2 weeks after removal of Mammosite
- Patient must be ineligible or have refused enrollment on the randomized trial RTOG
- T2 (>3.0 cm), T3, stage III or IV breast cancer.
- More then 3 histologically positive axillary nodes.
- Axillary nodes with evidence of extracapsular extension.
- Palpable or radiographically suspicious ipsilateral or contralateral axillary,
supraclavicular, infraclavicular or internal mammary nodes, unless biopsy proven to
be negative for tumor.
- Suspicious microcalcifications, densities or palpable abnormalities in either breast
unless biopsy proven to be benign.
- Non-epithelial breast malignancies such as sarcoma or lymphoma.
- Proven multicentric carcinoma in more than one quadrant or separated by more than 3
- Paget's disease of the nipple.
- History of invasive breast cancer or DCIS in the same breast.
- Surgical margins that cannot be microscopically assessed or are less then 2 mm.
- Collagen vascular disease, specifically dermatomyositis with a CPK level above normal
or with an active skin rash, systemic lupus erythematosis or scleroderma.
- Pregnancy or lactation at the time of proposed radiation. Women of reproductive
potential must agree to use an effective non-hormonal method of contraception during
- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements.
- Patients with coexisting medical conditions in whom life expectancy is < 2 years.
- Patients with skin involvement, regardless of tumor size.
- Patients for whom treatment with the MammoSite catheter is not feasible, such as
those with too little breast tissue between the skin and the catheter (<5mm).
- Yale University
- May 2006
- Last Updated:
- April 28, 2009
- Study HIC#:
Clinicaltrials.gov ID: NCT00611624